Evidence map›Paper›PMID 32818477›Full record

ReviewAmerican journal of obstetrics and gynecology2022

The role of statins in the prevention of preeclampsia.

Devin D Smith, Maged M Costantine

Open access · greenAbstract readReview
In one paragraph

Review in American journal of obstetrics and gynecology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 3 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 3 syntheses or guidelines pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Hypertensive disorders of pregnancy and women's health throughout the life course: an update review 2025-2026.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Review
  9. Article
  10. Preeclampsia trials that changed practice.Seminars in perinatology · 2026
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Devin D SmithDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH. Electronic address: devin.d.smith@gmail.com.
Maged M CostantineDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, Columbus, OH.
The Ohio State University · US

Funding

NICHD Maternal Fetal Medicine Units NetworkUG1HD027915 · NICHD · OHIO STATE UNIVERSITY · PI Maged Costantine · 2016 to 2026
$3.3M
1/2 A randomized controlled trial of pravastatin to prevent preeclampsia in high-risk womenUH3HL140131 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI COSTANTINE, MAGED · 2019 to 2023
$366k
1/2 A randomized controlled trial of pravastatin to prevent preeclampsia in high-risk womenUG3HL140131 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI COSTANTINE, MAGED, LAWRENCE CLEARY, KIRSTEN · 2018 to 2018
$153k
NHLBI NIH HHS UG3 HL140131NHLBI NIH HHS UH3 HL140131NICHD NIH HHS UG1 HD027915
6 · The paper itself

Abstract

Preeclampsia is a common hypertensive disorder of pregnancy associated with considerable neonatal and maternal morbidities and mortalities. However, the exact cause of preeclampsia remains unknown; it is generally accepted that abnormal placentation resulting in the release of soluble antiangiogenic factors, coupled with increased oxidative stress and inflammation, leads to systemic endothelial dysfunction and the clinical manifestations of the disease. Statins have been found to correct similar pathophysiological pathways that underlie the development of preeclampsia. Pravastatin, specifically, has been reported in various preclinical and clinical studies to reverse the pregnancy-specific angiogenic imbalance associated with preeclampsia, to restore global endothelial health, and to prevent oxidative and inflammatory injury. Human studies have found a favorable safety profile for pravastatin, and more recent evidence does not support the previous teratogenic concerns surrounding statins in pregnancy. With reassuring and positive findings from pilot studies and strong biological plausibility, statins should be investigated in large clinical randomized-controlled trials for the prevention of preeclampsia.

Indexed as

Abnormalities, Drug-InducedAnimalsEndothelium, VascularFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInflammationPre-EclampsiaPregnancyHydroxymethylglutaryl-CoA Reductase Inhibitorsangiogenesischolesterolcholesterol synthesishydroxymethylglutaryl-coenzyme A reductase inhibitorslipoproteinlow-density lipoproteinplacental growth factorpravastatinpreeclampsiapreventionsoluble endoglinsoluble fms-like tyrosine kinasestatinsvascular endothelial growth factor

Identifiers

PMID32818477
PMCPMC8237152
OpenAlexW3049359994

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.